Preclinical efficacy & intermediate endpoint biomarkers IDIQ contract in support of the prevent cancer preclinical drug development program
Active Awarded Last action
- Contract number
- 75N91024D00006
- Awardee
-
Weill Medical College Of Cornell University UEI YNT8TCJH8FQ8
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 0
Award facts
- Opportunity
-
- Prevent IDIQ mato RFP Pre-Solicitation · 75N91023R00024 · Posted Dec 19, 2022
- Last date to order 55% complete
- IDV ceiling
- $149,995,000.00
- Maximum order
- $149,995,000.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 9 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The National Cancer Institute awarded an indefinite-delivery contract to Weill Medical College of Cornell University on January 25, 2024, with a ceiling of $149,995,000 and ultimate completion date of January 24, 2029. This is a multiple-award vehicle with no set-aside. The contract supports the PREVENT Cancer Preclinical Drug Development Program, delivering specialized preclinical research services including biomarker identification, analytical assay development, and drug efficacy evaluation. Work is performed at Weill Medical College's New York, New York location and subordinate facilities. The originating solicitation, posted on December 19, 2022, closed on February 6, 2023, and requested preclinical efficacy and intermediate endpoint biomarkers services in support of Executive Order 14398 cancer prevention priorities. The contract period runs through January 24, 2029 with no stated options explicitly described.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N91024D00006?
75N91024D00006 was awarded to Weill Medical College Of Cornell University by National Cancer Institute (National Institutes of Health) on January 25, 2024.
How much is contract 75N91024D00006 worth?
75N91024D00006's own ceiling is $149,995,000. A single order can be worth up to $149,995,000.
Who can order from contract 75N91024D00006?
75N91024D00006 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract 75N91024D00006 part of a contract vehicle?
Yes. 75N91024D00006 is part of PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ.
Was contract 75N91024D00006 competed?
The extent of competition for 75N91024D00006 was full and open competition. The government received 9 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV